This phase 3 trial tests whether adding afuresertib (a targeted drug) to fulvestrant (a standard hormone therapy) can help control advanced HR+/HER2- breast cancer that has stopped responding to other treatments. The study includes 256 adults with specific genetic changes (PIK3CA…
Phase: PHASE3 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC